EGFR and hepatocellular carcinoma: On the contrary, the expression level of EGFR can also be reduced by inhibiting phosphorylation to inhibit the MAPK pathway.[20] The activation of the EGFR/MAPK pathway can promote the occurrence and metastasis of various cancers, such as hepatocellular carcinoma and oesophageal cancer.[21,22]